PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02553356
Recruitment Status : Completed
First Posted : September 17, 2015
Last Update Posted : December 10, 2015
Information provided by (Responsible Party):
Peloton Therapeutics, Inc.

Brief Summary:
This Phase 1, single-dose study will be conducted in adult female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of PT2385 Tablets. The study will consist of two periods and will be conducted in a crossover fashion.

Condition or disease Intervention/treatment Phase
Healthy Drug: PT2385 Phase 1

Detailed Description:
Subjects will be randomized in equal numbers to two sequences of meal conditions (fasting and non-fasting). Serial blood samples will be collected for after dose administration in each period. Subjects will be confined at the clinical research for a portion of each period.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2385 Tablets
Study Start Date : September 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: Fasted
PT2385 taken after fasting.
Drug: PT2385
Experimental: Non-Fasting
PT2385 taken after eating a high calorie meal.
Drug: PT2385

Primary Outcome Measures :
  1. Effect of food on the pharmacokinetics of a single dose of PT2385 Tablets administered to normal healthy adult subjects (Cmax). [ Time Frame: 6 days ]
    Peak Plasma Concentration (Cmax) will be assessed in both the fasting and non-fasting conditions and compared.

Secondary Outcome Measures :
  1. Safety and tolerability of PT2385 Tablets in normal healthy adult subjects by reviewing the incidence of treatment-emergent adverse events. [ Time Frame: 30 days ]
    Analyses will consist of data summaries for AEs/SAEs

  2. Pharmacodynamic (PD) effects of treatment with PT2385 Tablets (plasma levels). [ Time Frame: 6 days ]
    Variability in biomarkers will be correlated with plasma levels of PT2385.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female between 18 and 45 years of age;
  • If of childbearing potential, willing to practice methods of birth control;
  • If of childbearing potential, must be non-pregnant and non-lactating and have a negative serum pregnancy test result prior to enrollment into the trial;
  • Has a body mass index (BMI) between 19 and 32 kg/m2;
  • Willing and able to give written informed consent for study participation and provide consent for access to medical data;
  • Willing and able to cooperate with all aspects of the protocol.

Exclusion Criteria:

  • Any vaccination within 30 days before start of this study and throughout the study;
  • Use of or need for any systemic drug(s) including vitamins or herbal preparations other than drugs used for contraception, within 30 days before entry into the study or during the study;
  • Use of aspirin, non-steroidal anti-inflammatory agents, or acetaminophen within 5 days prior to the ingestion of the study drug;
  • Donation or receipt of blood or blood components within the 4 weeks prior to the start of the study;
  • Any diagnostic or intervention procedure requiring a contrast agent within the 30 days prior to the start of study participation;
  • Abnormal blood pressure or pulse rate;
  • Abnormal screening electrocardiogram (ECG);
  • Use of tobacco or nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, etc.);
  • Consumption of alcohol or xanthine-containing products;
  • Consumption of grapefruit, star fruit, Seville oranges, or products containing any of these ingredients;
  • Receipt of any investigational agent within 30 days;
  • A positive history of drug abuse or a positive test result for drug(s) of abuse;
  • Female subjects who are planning a pregnancy or are pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02553356

United States, Wisconsin
Spaulding Clinical
West Bend, Wisconsin, United States
Sponsors and Collaborators
Peloton Therapeutics, Inc.

Responsible Party: Peloton Therapeutics, Inc. Identifier: NCT02553356     History of Changes
Other Study ID Numbers: PT2385-102
First Posted: September 17, 2015    Key Record Dates
Last Update Posted: December 10, 2015
Last Verified: December 2015

Keywords provided by Peloton Therapeutics, Inc.:
Female Subjects